Haixiang Pharmaceutical, Xianju Pharmaceutical and other stocks were investigated by Jinxin Fund

According to market public information and institutional research information disclosed on November 25, Jinxin Fund recently conducted research on 5 listed companies, including two pharmaceutical companies, namely Haixiang Pharmaceutical and Xianju Pharmaceutical
.
The other three companies are Yitian Intelligence, Subpotassium International, and Jingtest Electronics
.
It is understood that Haixiang Pharmaceutical is a comprehensive Peinan supplier
of the whole industry chain.
Peinan (high-end anti-infective drugs, suitable for severe infection, nosocomial infection, multi-drug resistant bacteria infection and mixed infection) has a long industrial chain, products from primary raw materials to API involving more than ten intermediates, the company can produce the main materials in the Peinan industrial chain, and is also actively deploying sterile APIs
.
In the past two years, the company has been improving and opening up the front-end industrial chain, and completed the expansion of production capacity in the fourth quarter of last year, forming advantages in supply chain stability, safety, production capacity and output scale
.
Thanks to the sufficient supply of supporting intermediates, the revenue of the Penan series has increased significantly year-on-year this year, and profitability has gradually recovered
.
In recent years, Haixiang Pharmaceutical has been increasing investment in R&D, investing in the construction of an enzyme biology laboratory in Shanghai, and building a characteristic enzyme biology platform and professional team; In Taizhou, we invested in the construction of a biological fermentation platform, and just obtained 45 acres of land to plan to build a headquarters research institute and a pilot workshop to continuously improve the strength
of R&D software and hardware.
Relying on various characteristic platforms, more than ten APIs and intermediates have been laid out, and the new products involve immunology, hepatobiliary, ophthalmic drugs, antifungal, psychiatric and other therapeutic fields, including 3 semi-fermented and semi-synthetic products, and 3 existing product process innovations using enzyme catalytic platforms
.
In addition, the company has independently operated the CMO/CDMO business unit and increased investment and expansion
on the BD side.
According to the third quarter report of Haixiang Pharmaceutical in 2022, the company's main revenue was 2.
071 billion yuan, a year-on-year increase of 15.
63%; net profit attributable to owners was 207 million yuan, up 170.
17% year-on-year; Non-net profit was RMB233 million, up 401.
08%
year-on-year.
Xianju Pharmaceutical is mainly engaged in the development, production and sales of steroidal APIs and preparations; The main products include progesterone capsules
.
According to the third quarter report of Xianju Pharmaceutical in 2022, the company's main revenue was 3.
453 billion yuan, a year-on-year increase of 4.
09%; net profit attributable to owners was RMB529 million, up 15.
24% year-on-year; Non-net profit was RMB498 million, up 11.
18%
year-on-year.
Xianju Pharmaceutical said that the company has built a superior manufacturing platform
around cost, quality and efficiency in the production of API products.
In the high-end industrial chain to sterile APIs, API customization and other directions, look for advantageous varieties, and strive to develop high-end product customers
.
Expand in the API industry chain, seek to improve the cost and quantity, integrate the application of new technologies such as synthetic biology and enzyme catalysis, and strive to contribute
technology to the API industry chain 。 From the perspective of product declaration or approval, Xianju Pharmaceutical's prednisolone tablets were evaluated in June 2022, and the API and preparation of Sugenglucosa sodium were approved in July 2022, and progesterone sustained-release gel was declared in August 2022, and besysulfoncis-atracurium injection was approved in September 2022, dexamethasone sodium phosphate injection was evaluated in November 2022, and the consistency evaluation of vecuronium bromide for injection was accepted
in November 2022 。 The company has planned to introduce the existing key new products into the market, and the new product norethindrone heptanoate injection has been rapidly introduced
in the second and third quarters of this year.
Sugamon Glucose Injection went on sale in September and is currently in the introduction period
.
Lay the groundwork
for a new increment next year.
It is reported that through market investigation and positioning, Xianju Pharmaceutical will set up product groups in various therapeutic fields to find and obtain the required potential products and varieties with relatively good competition pattern, so as to make product reserves
for the company's sustainable and steady development in the future.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.